

WHAT A MANUFACTURER OR VAPE SHOP OWNER SHOULD DO AFTER RECEIVING A WARNING LETTER

Disclaimer: This is not a formal dissemination of information by FDA and does not represent Agency position or policy.

AGENDA

- Responding to a Warning Letter
- Resources



RESPONDING TO A WARNING LETTER

RESPONDING TO A WARNING LETTER

Carefully read the letter and address the issues raised. The written response should be directed to the address listed in the Warning Letter and should include:

- Current contact information, including address, telephone number, and e-mail address
- The reference number listed at the bottom of the Warning Letter

RESPONDING TO A WARNING LETTER

Warning Letter responses may include:

- Each step taken or that will be taken to completely correct the current violations and prevent similar violations
- The precise time it will take to make any corrections
- Any reason the corrective action cannot be completed within a timely manner (if applicable)
- Any documentation necessary to show that corrective actions have been made. This should also include documentation demonstrating the destruction, disposal or reconditioning of all violative products, where applicable

See Chapter 4 of the [Regulatory Procedures Manual Feb 2022](#) for more information.

RESPONDING TO A WARNING LETTER

- If you have any questions about the content of a Warning Letter please contact CTPCompliance@fda.hhs.gov
- If you believe your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration
- It is always the manufacturer's responsibility to ensure that it complies with each applicable provision of the FD&C Act and FDA's implementing regulations. Neither responding nor failing to respond to a Warning Letter absolves a manufacturer of that continuing responsibility.

POST WARNING LETTER ACTIONS

- FDA may contact you if additional information or clarification is needed regarding your response
- FDA will typically conduct follow-up inspections at your establishment.
- If continued violations are observed during a follow-up inspection, it may result in FDA taking enforcement action without notice, including, but not limited to, civil money penalties, seizure, or injunction.

QUESTIONS

- If you have any questions about the content of a Warning Letter please contact CTPCompliance@fda.hhs.gov
- General inquiries can be sent to ASKCTP@fda.hhs.gov or by calling 1-877-287-1373
- For all small business questions contact the Office of Small Business Assistance at Smallbiz.tobacco@fda.hhs.gov
- The CTP Ombudsman's Office provides a “safe space” for stakeholders to voice their questions, concerns, or complaints about FDA regulation of tobacco products, and can be reached at [CTP Ombudsman | FDA](#)



RESOURCES

RESOURCES AND CONTACTS

CTP Website available at:

<http://www.fda.gov/TobaccoProducts/default.htm>

For General Inquiries contact via email or phone:

AskCTP@fda.hhs.gov 1-877-CTP (287)-1373

Inquiries from small businesses:

Smallbiz.tobacco@fda.hhs.gov

[CTP Ombudsman | FDA](#)

Sign up for [“CTP News”](#) and [“CTP Connect”](#) to receive CTP’s email updates.

ADDITIONAL RESOURCES

Additional information on the pathways to market a new tobacco product can be found at the [Market and Distribute a Tobacco Product](#) page of the FDA website.

ADDITIONAL RESOURCES

[Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments](#)

Registration and Listing mailbox:
CTPRegistrationandListing@fda.hhs.gov

[The Tobacco Registration and Product Listing Updates Webinar](#)

ADDITIONAL RESOURCES

Provision(s)	Resources and References
<p>Premarket tobacco product authorization required for tobacco products unless:</p> <ul style="list-style-type: none">• FDA has issued a substantial equivalence (SE) order for the tobacco product• FDA has granted a substantial equivalence exemption request• The product was on the market as of February 15, 2007, and has remained unchanged since then (Pre-Existing). <p>(§§ 910 and 905(j) of the FD&C Act)</p>	<p><u>Section 905</u> of the FD&C Act</p> <p><u>Section 910</u> of the FD&C Act</p> <p>FDA Guidance for Industry: <u>Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS)</u></p>

ADDITIONAL RESOURCES

Additional information can be found below:

[FDA Tobacco Compliance Webinars](#)

[FDA Regulatory Procedures Manual](#)

[CTP Regulations](#)

[CTP Guidance Documents](#)